The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > 79th American Diabetes Association Scientific Sessions (June 7-11, 2019) in San Francisco, California.

News detail

Return to all news & events

05/31/2019 79th American Diabetes Association Scientific Sessions (June 7-11, 2019) in San Francisco, California.

Physiogenex will be presenting a poster on Monday, June 10, 2019 12:00 PM – 01:00 PM at the American Diabetes Association’s 79th Scientific Sessions on June 7-11 in San Francisco.

Dr. François Briand, our Director of Research and Business Development, will be present at this event. He will be happy to discuss with you about your preclinical diabetes projects.

Please Contact us if you wish to set up an appointment.

About us

Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.